Up to 90% of cancer-related deaths can be attributed to the development of treatment resistance, with 70% of aggressive cancers exhibiting resistance to conventional treatment. The primary culprits are Cancer Stem Cells (CSC), a tumours subpopulation with the capacity of self-renewal and differentiation, known to participate in tumor initiation, progression and metastasis. CSC are hard to eradicate and contribute to cancer relapse even years after therapy cessation. CSC reside within immunosuppressive tumor microenvironments that hinders the normal functioning of patients' own immune cells and impairs their ability to recognize and eliminate cancer cells effectively. Although significant progress has been made in the development of immunotherapies, current therapies are not specifically targeted against CSC and their clinical application is still restricted to treating only a small number of cancers.
We are employing innovative Induced Pluripotent Stem Cells (iPSC)-based immunotherapies against CSC and aggressive forms of cancers to solve the three major hurdles associated with cancer treatment: metastasis, treatment resistance, and relapse.
iPSirius' proprietary technology, IPVAC 1.0 enables patients' immune system to specifically recognize and respond to thousands of antigens found in CSC while converting the tumor microenvironment from a state where the immune system is suppressed to a state where it becomes more active and responsive. This means shifting the conditions within the tumor to make it easier for the immune system to recognize and attack cancer cells. With IPVAC 1.0 we aim to enhance the body's natural defense mechanisms and improve the chances of effectively eradicating CSC, the root of cancer.